Bridgefront Capital’s Ultragenyx Pharmaceutical RARE Stock Holding History

Bridgefront Capital’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-35,135	Closed	-$736K	–	700
2026 Q1	$736K	Buy	+35,135	New	+$791K	0.18%	185
2025 Q4	–	Sell	-9,385	Closed	-$282K	–	737
2025 Q3	$282K	Buy	+9,385	New	+$281K	0.08%	416
2023 Q3	–	Sell	-5,702	Closed	-$263K	–	568
2023 Q2	$263K	Buy	+5,702	New	+$264K	0.14%	301
2021 Q1	–	Sell	-2,490	Closed	-$345K	–	874
2020 Q4	$345K	Buy	+2,490	New	+$295K	0.12%	325

Other funds holding RARE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Bridgefront Capital's RARE Position: Q2 2026 in Review

Bridgefront Capital sold out of Ultragenyx Pharmaceutical (RARE) in Q2 2026, closing a stake of 35,135 shares — an estimated $736K sold.

Bridgefront Capital first reported a position in RARE in Q4 2020 and held it in 4 quarters. The position peaked at $736K in Q1 2026. 311 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

Bridgefront Capital reported no remaining Ultragenyx Pharmaceutical position as of Q2 2026 after selling out during the quarter.
Bridgefront Capital sold 35,135 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $736K.
Bridgefront Capital first reported a position in Ultragenyx Pharmaceutical in Q4 2020 and held it in 4 quarters.
Bridgefront Capital's Ultragenyx Pharmaceutical position peaked at $736K in Q1 2026.
311 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Bridgefront Capital's 13F filing for Q2 2026, filed 14 Aug 2026.